The driving motivation behind Ireland's National Institute for Bioprocessing Research and Training (NIBRT) is to help the development of the biopharmaceutical, by developing comprehensive research and training programs for both academic students and industry professionals.
World-Class Biopharmaceutical Training for Academia and Industry
The driving motivation behind Ireland's National Institute for Bioprocessing Research and Training (NIBRT) is to help the development of the biopharmaceutical, by developing comprehensive research and training programs for both academic students and industry professionals. By ensuring the creation and sustainability of the biopharmaceutical workforce with superior skills and competencies, the promise of more effective biotherapeutic innovations addressing the world's most challenging diseases is becoming a reality.
NIBRT provides a “one stop shop” for thousands of trainees worldwide, and offers a dynamic catalogue of course content from which unique training solutions are built for clients. NIBRT delivers holistic training programs in a realistic GMP-simulated, fully operational manufacturing environment and cutting-edge analytical laboratory suite. All training programmes can be customized to meet a client’s particular requirements.
NIBRT Key Features:
Get the most comprehensive overviews of the concepts, strategies and techniques – on all aspects of bioprocessing. Book your course today.
http://www.nibrt.ie/cat_training_schedule.jsp
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Large-Scale LNP Process Conversions: The many hurdles of LNP scale-up and what to consider
May 12th 2025Lipid nanoparticle (LNP) formulation development begins on a small scale, often with homemade or benchtop setups, using syringe pumps and easily accessible micro-mixing systems. Once a promising formulation has been identified, the next step is to transition to standardized large-scale impingement mixing systems, such as the high flow T-mixing pumps that were used to produce the COVID-19 vaccines (Sealy 2021). Formulators need to consider a number of factors when scaling up novel LNP systems. These include flow rates that affect LNP particles, solvent removal, risk factors when changing equipment, and the impact of tangential flow filtration sensitivity. In this technical note, we discuss these factors and what needs to be considered when developing a cost- and time efficient large-scale process.